Literature DB >> 1328433

Combination treatment with ribavirin and interferon for coxsackievirus B3 replication.

I Okada1, A Matsumori, Y Matoba, M Tominaga, T Yamada, C Kawai.   

Abstract

The effects of combined treatment with ribavirin and recombinant human leukocyte interferon-alpha A/D against Coxsackievirus B3 replication were investigated in cultured cells. Recombinant human leukocyte interferon-alpha A/D was applied 12 hours before Coxsackievirus B3 inoculation and ribavirin was applied 1 hour after Coxsackievirus B3 inoculation on FL (human amnion) cell monolayers. These drugs inhibited Coxsackievirus B3 replication synergistically by plaque-reduction assay. This method of applying drugs may be useful in preventing and treating Coxsackie B virus infection.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1328433

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN： 0022-2143


  9 in total

1.  The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis.

Authors:  C Zaragoza; C Ocampo; M Saura; M Leppo; X Q Wei; R Quick; S Moncada; F Y Liew; C J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 2.  Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.

Authors:  Chandirasegaran Massilamany; Arunakumar Gangaplara; Jay Reddy
Journal:  Int J Cardiol       Date:  2014-10-18       Impact factor: 4.164

Review 3.  Diagnosis and treatment of viral myocarditis.

Authors:  Jason C Schultz; Anthony A Hilliard; Leslie T Cooper; Charanjit S Rihal
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 4.  Myocarditis.

Authors:  Leslie T Cooper
Journal:  N Engl J Med       Date:  2009-04-09       Impact factor: 91.245

5.  The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.

Authors:  Elizaveta Padalko; Dieter Nuyens; Armando De Palma; Erik Verbeken; Joeri L Aerts; Erik De Clercq; Peter Carmeliet; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 6.  Myocarditis.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Prog Cardiovasc Dis       Date:  2010 Jan-Feb       Impact factor: 8.194

7.  Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis.

Authors:  Zhijian Yu; Zhen Huang; Chongwen Shao; Yuanjian Huang; Fan Zhang; Jin Yang; Lili Deng; Zhongming Zeng; Qiwen Deng; Weiseng Zeng
Journal:  Virol J       Date:  2011-12-08       Impact factor: 4.099

8.  Berberine Restricts Coxsackievirus B Type 3 Replication via Inhibition of c-Jun N-Terminal Kinase (JNK) and p38 MAPK Activation In Vitro.

Authors:  Qian Dai; Di Zhang; Hua Yu; Wei Xie; Rong Xin; Lei Wang; Xiaohui Xu; Xiaomei He; Junzhi Xiong; Halei Sheng; Le Zhang; Kebin Zhang; Xiaomei Hu
Journal:  Med Sci Monit       Date:  2017-03-25

9.  Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis.

Authors:  Shirin Kalimuddin; October M Sessions; Yan'An Hou; Eng Eong Ooi; David Sim; Sivathasan Cumaraswamy; Teing Ee Tan; Siang Hui Lai; Chian Yong Low
Journal:  J Clin Virol       Date:  2012-11-06       Impact factor: 3.168
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.